QLI: מקדם מחיר להכנסות Qilian International Holding Group Limited

Qilian International operations are restricted by strict FDA medical regulations regarding the disposal of biomaterials. The price-to-sales trend clearly demonstrates the business's resilience to shocks, with the indicator reaching 4.20. The growth of biologics is driven by synergy with Chinese agricultural holdings, although trade wars with the US create risks of Western capital blockages and more stringent quality audits.

The price-to-sales ratio dynamics for Qilian International (QLI) on the GURU.Markets platform reflect the impact of drug portfolio diversification and raw material supply stability on the business's market valuation. This multiple, calculated as the ratio of market capitalization to annual revenue, determines whether the asset is overvalued or if the capital is undervalued relative to the company's actual operational cash flows.